Clinical Trials · NCT06778967

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

Active Not RecruitingPhase 3Semaglutide (Investigational)
Phase
Phase 3
Recruitment status
Active Not Recruiting
Sponsor
Gan & Lee Pharmaceuticals.
Enrollment
1,100
Start date
Feb 2025
Locations
1 site, China
Primary endpoint
Change from Baseline in Hemoglobin A1c (HbA1c)(%)
View Semaglutide compound reference